Oakland, CA, United States of America

Michael Mamounas



Average Co-Inventor Count = 17.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michael Mamounas: Innovator in Protein Kinase Inhibitors

Introduction

Michael Mamounas is a notable inventor based in Oakland, CA. He has made significant contributions to the field of medicinal chemistry, particularly in the development of novel compounds with therapeutic potential. His work focuses on creating innovative solutions for complex medical challenges.

Latest Patents

One of Michael Mamounas's key inventions is a patent for dihydropyridine derivatives that serve as protein kinase inhibitors. This invention provides novel dihydropyridine derivatives of the formula I, which exhibit protein tyrosine kinase inhibitory activity. The patent outlines a process for the manufacture of these compounds and their use in treating c-Met-mediated diseases or conditions. He holds 1 patent related to this groundbreaking work.

Career Highlights

Michael Mamounas is currently associated with Bayer Intellectual Property GmbH, where he continues to advance his research and development efforts. His expertise in medicinal chemistry and innovative thinking has positioned him as a valuable asset in the pharmaceutical industry.

Collaborations

Throughout his career, Michael has collaborated with esteemed colleagues, including Marc Adler and Stefan Baeurle. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries.

Conclusion

Michael Mamounas exemplifies the spirit of innovation in the field of medicinal chemistry. His contributions, particularly in the development of protein kinase inhibitors, highlight the importance of research in addressing medical challenges. His work continues to inspire future advancements in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…